IP Library Assignment 073116/0803
Patent Assignment
Reel/Frame 073116/0803

Assignment of Assignor's Interest

Recorded: 2025-10-20 Pages: 13
Assignor
BEIGENE, LTD.
Executed: 2025-09-30
Assignee
BEONE MEDICINES I GMBH
AESCHENGRABEN 27, BASEL, 4051, SWITZERLAND
Covered Properties (73)
Fused Tricyclic Compounds as Raf Kinase Inhibitors
Patent: 9,273,046 →
Application: 14/369,379 →
Publication: US 2015/0045355
Fused Tricyclic Compounds as Raf Kinase Inhibitors
Patent: 9,895,376 →
Application: 15/004,311 →
Publication: US 2016/0206621
Fused Tricyclic Compounds as Raf Kinase Inhibitors
Application: 15/882,064 →
Publication: US 2019/0000857
Maleate Salts of a B-Raf Kinase Inhibitor, Crystalline Forms, Methods of Preparation, and Uses Therefore
Application: 15/565,807 →
Publication: US 2018/0127412
SUBSTITUTED CYCLOOCTA[5,6]PYRIDO[4,3,2-de]PHTHALAZINES AS PARP INHIBITORS
Patent: 9,328,111 →
Application: 14/369,388 →
Publication: US 2015/0018356
Substituted 5-(3,5-Dimethylisoxazol-4-Yl)Indoline-2-Ones
Patent: 9,393,232 →
Application: 14/404,798 →
Publication: US 2016/0030395
Substituted 5-(3,5-Dimethylisoxazol-4-Yl)Indoline-2-Ones
Patent: 9,827,226 →
Application: 15/174,229 →
Publication: US 2017/0027912
Fused Tricyclic Urea Compounds as Raf Kinase and/or Raf Kinase Dimer Inhibitors
Patent: 9,920,055 →
Application: 15/581,728 →
Publication: US 2017/0233391
Fused Tricyclic Urea Compounds as Raf Kinase and/or Raf Kinase Dimer Inhibitors
Application: 15/882,067 →
Publication: US 2018/0282326
Fused Tricyclic Urea Compounds as Raf Kinase and/or Raf Kinase Dimer Inhibitors
Application: 16/243,301 →
Publication: US 2019/0144446
Fused Tricyclic Urea Compounds as Raf Kinase and/or Raf Kinase Dimer Inhibitors
Patent: 9,670,203 →
Application: 14/901,634 →
Publication: US 2016/0368914
NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
Application: 15/564,666 →
Publication: US 2018/0072716
Novel 5 or 8-Substituted Imidazo[1,5-a]Pyridines as Indoleamine and/or Tryptophane 2,3-Dioxygenases
Application: 16/366,353 →
Publication: US 2019/0284184
5 OR 8-SUBSTITUTED IMIDAZO [1,5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2,3-DIOXYGENASES
Application: 16/335,811 →
Publication: US 2020/0024273
CRYSTALLINE FORMS OF (S)-7-(1-(BUT-2-YNOYL)PIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRAHYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF
Application: 16/479,709 →
Publication: US 2021/0332049
Pyrazolotriazolopyrimidine Derivatives as A2A Receptor Antagonist
Application: 16/982,681 →
Publication: US 2021/0198267
IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS
Application: 16/466,621 →
Publication: US 2019/0367523
IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS
Application: 17/370,728 →
Publication: US 2022/0098202
Imidazo[1,5-A]Pyrazine Derivatives as PI3KDELTA Inhibitors
Application: 16/643,040 →
Publication: US 2020/0207774
Btk Inhibitors with Improved Dual Selectivity
Application: 16/637,615 →
Publication: US 2020/0181150
Novel Benzoimidazoles as Selective Inhibitors of Indoleamine 2,3-Dioxygenases
Application: 16/758,203 →
Publication: US 2020/0317638
Imidazo[2,1-F][1,2,4]Triazin-4-Amine Derivatives as TLR7 Agonist
Application: 17/428,856 →
Publication: US 2022/0119394
Immunotherapy for Hepatocellular Carcinoma
Application: 16/621,342 →
Publication: US 2021/0147543
Anti-Pd-L1 Antibodies and Their Use as Therapeutics and Diagnostics
Application: 15/323,153 →
Publication: US 2018/0215825
Anti-Pd-L1 Antibodies and Their Use as Therapeutics and Diagnostics
Application: 16/704,738 →
Publication: US 2020/0283527
Anti-OX40 Antibodies and Methods of Use
Application: 17/055,267 →
Publication: US 2021/0214452
Imidazo[1,5-A]Pyrazine Derivatives as PI3KDELTA Inhibitors
Application: 17/533,442 →
Publication: US 2022/0081447
Bcl-2 Inhibitor
Application: 17/916,845 →
Publication: US 2023/0159522
3-[(1H-Pyrazol-R-Yl)Oxy]Pyrazin-2-Amine Compounds as HPK1 Inhibitor and Use Thereof
Application: 18/650,207 →
Publication: US 2024/0317714
Cyclic Dinucleotides as Sting Agonists
Application: 17/629,466 →
Publication: US 2022/0251135
Imidazo[2,1-F][1,2,4]Triazin-4-Amine Derivatives Used as TLR8 Agonists
Application: 17/632,027 →
Publication: US 2022/0289752
Pyrazolotriazolopyrimidine Derivatives as A2A Receptor Antagonist
Application: 17/261,359 →
Publication: US 2021/0300936
Stable Solid Dispersion of a B-Raf Kinase Dimer Inhibitor, Methods of Preparation, and Uses Therefor
Application: 17/423,600 →
Publication: US 2022/0105033
Bcl-2 INHIBITORS
Application: 17/771,871 →
Publication: US 2023/0002369
Inhibitors of Kras G12C
Application: 17/763,720 →
Publication: US 2022/0389021
Imidazo[2,1-F][1,2,4]Triazin-4-Amine Derivatives as TLR7 Agonist
Application: 17/428,853 →
Publication: US 2023/0167117
Amide-Substituted Imidazo Compounds as Selective Inhibitors of Indoleamine 2,3-Dioxygenases
Application: 17/612,056 →
Publication: US 2022/0227762
Degradation of Bruton's Tyrosine Kinase (Btk) by Conjugation of Btk Inhibitors with E3 Ligase Ligand and Methods of Use
Application: 17/629,910 →
Publication: US 2022/0281876
Aminopyrazine Compounds as HPK1 Inhibitor and the Use Thereof
Application: 17/636,473 →
Publication: US 2022/0289712
Substituted Pyrazoles as Sting Modulators
Application: 17/767,115 →
Publication: US 2022/0289768
Tyk-2 Inhibitor
Application: 17/801,551 →
Publication: US 2023/0159520
Degradation of Bruton's Tyrosine Kinase (Btk) by Conjugation of Btk Inhibitors with E3 Ligase Ligand and Methods of Use
Application: 17/910,037 →
Publication: US 2023/0322761
(R) AND (S)-3-(TERT-BUTYL)-N-(1-(4-(6-(6-(4-((1-(4-(2,4-DIOXOTETRAHYDROPYRIMIDIN-1(2H)-YL)PHENYL)PIPERIDIN-4-YL)METHYL)PIPERAZIN-1-YL)PYRIDIN-3-YL)-7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-2-METHYLPHENYL)ETHYL)-1,2,4-OXADIAZOLE-5-CARBOXAMIDE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS
Application: 17/919,847 →
Publication: US 2023/0167118
Heterocyclic Compounds as Sting Modulators
Application: 17/925,854 →
Publication: US 2023/0212192
Pyrido[2,3-B][1,4]Oxazines or Tetrahydropyrido[2,3-B][1,4]Oxazepines as Iap Antagonists
Application: 17/928,949 →
Publication: US 2023/0219975
Interleukin 15 Constructs and Methods of Use
Application: 18/245,654 →
Publication: US 2023/0357344
Imidazotriazine and Pyrrolopyrimidine Derivatives as Kras G12C Inhibitors
Application: 18/040,667 →
Publication: US 2023/0322788
Tyk-2 Inhibitor
Application: 18/011,590 →
Publication: US 2024/0043435
Indoline Compounds and Derivatives as Egfr Inhibitors
Application: 18/027,665 →
Publication: US 2023/0373960
Degradation of (Egfr) by Conjugation of Egfr Inhibitors with E3 Ligase Ligand and Methods of Use
Application: 18/015,561 →
Publication: US 2023/0248834
Bifunctional Compounds for Degradation of Egfr and Related Methods of Use
Application: 18/029,227 →
Publication: US 2024/0025902
Degradation of (Egfr) by Conjugation of Egfr Inhibitors with E3 Ligase Ligand and Methods of Use
Application: 18/016,292 →
Publication: US 2023/0265116
Heterocyclic Compounds, Compositions Thereof, and Methods of Treatment Therewith
Application: 18/597,844 →
Publication: US 2024/0262848
Substituted 6-(Pyrimidin-4-yl)Quinoline Compounds as Cyclin Dependent Kinase Inhibitors
Application: 18/623,847 →
Publication: US 2024/0300937
Degradation of (Egfr) by Conjugation of Egfr Inhibitors with E3 Ligase Ligand and Methods of Use
Application: 18/771,529 →
Publication: US 2024/0368203
4-(Aminomethyl)-6-(1-Methyl-1H-Pyrazol-4-YL)Isoquinolin-1(2H)-One Derivatives as MTA-Cooperative Inhibitors of PRMT5
Application: 18/825,776 →
Publication: US 2025/0000854
Heterocyclic Compounds, Compositions Thereof, and Methods of Treatment Therewith
Application: 18/889,657 →
Publication: US 2025/0101028
Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors
Application: 18/761,919 →
Publication: US 2025/0026766
Bcl-Xl Inhibitors
Application: 18/894,069 →
Publication: US 2025/0034128
Heterocyclic Compounds, Compositions Thereof, and Methods of Treatment Therewith
Application: 18/796,700 →
Publication: US 2025/0163047
Bcl-2 Inhibitors
Application: 18/745,423 →
Publication: US 2024/0376104
Small Molecule IL-17A Modulators
Application: 18/918,712 →
Publication: US 2025/0154138
Heterocyclic Compounds, Compositions Thereof, and Methods of Treatment Therewith
Application: 18/934,390 →
Publication: US 2025/0066372
Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
Application: 18/926,544 →
Publication: US 2025/0136586
Degradation of IRAK4 by Conjugation of IRAK4 Inhibitors with E3 Ligase Ligand and Methods of Use
Application: 18/972,490 →
Publication: US 2025/0195513
Antibody Drug Conjugates
Application: 18/971,958 →
Publication: US 2025/0099607
Anti-CCR8 Antibodies and Methods of Use
Application: 18/930,933 →
Publication: US 2025/0115671
Anti-cMET Antibodies and Methods of Use
Application: 18/957,490 →
Publication: US 2025/0154265
Anti-GPC3 and Anti-CD137 Multispecific Antibodies and Methods of Use
Application: 18/954,427 →
Publication: US 2025/0154279
Anti-FGFR2b Antibodies, Conjugates and Methods of Use
Application: 19/008,844 →
Publication: US 2025/0222125
Heterocyclic Compounds, Compositions Thereof, and Methods of Treatment Therewith
Application: 19/011,372 →
Publication: US 2025/0221996
BCL-2 Inhibitor
Application: 19/035,219 →
Publication: US 2025/0270210
3-[(1H-Pyrazol-4-Yl)Oxy]Pyrazin-2-Amine Compounds as HPK1 Inhibitor and Use Thereof
Application: 19/176,735 →
Publication: US 2025/0236610
Related Assignments (18)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Oct 23, 2014
From: ZHOU, CHANGYOU; ZHANG, GUOLIANG; WANG, SHAOHUI
To: BEIGENE LTD.
Reel/Frame 034022/0461 →
Assignment of Assignor's Interest Mar 5, 2015
From: ZHOU, CHANGYOU; REN, BO; WANG, HEXIANG
To: BEIGENE LTD.
Reel/Frame 035097/0705 →
Assignment of Assignor's Interest Aug 20, 2015
From: REN, BO; ZHOU, CHANGYOU; WANG, HEXIANG
To: BEIGENE, LTD.
Reel/Frame 036381/0842 →
Assignment of Assignor's Interest Jan 25, 2016
From: ZHOU, CHANGYOU; WANG, SHAOHUI; ZHANG, GUOLIANG
To: BEIGENE, LTD.
Reel/Frame 037572/0528 →
Assignment of Assignor's Interest Jan 26, 2016
From: ZHOU, CHANGYOU; ZHANG, GUOLIANG
To: BEIGENE, LTD.
Reel/Frame 037592/0195 →
Assignment of Assignor's Interest Sep 29, 2016
From: REN, BO; WANG, HEXIANG; ZHOU, CHANGYOU
To: BEIGENE LTD.
Reel/Frame 039892/0629 →
Assignment of Assignor's Interest Jun 26, 2017
From: ZHOU, CHANGYOU; ZHANG, GUOLIANG
To: BEIGENE, LTD.
Reel/Frame 042815/0140 →
Assignment of Assignor's Interest Oct 12, 2017
From: WANG, HEXIANG; ZHANG, GUOLIANG; GUO, YUNHANG; REN, BO
To: BEIGENE, LTD.
Reel/Frame 043844/0199 →
Assignment of Assignor's Interest Oct 12, 2017
From: ZHANG, GUOLIANG; ZHOU, CHANGYOU
To: BEIGENE, LTD.
Reel/Frame 043845/0814 →
Assignment of Assignor's Interest Jan 31, 2018
From: ZHOU, CHANGYOU; WANG, SHAOHUI; ZHANG, GUOLIANG
To: BEIGENE, LTD.
Reel/Frame 044781/0664 →
Assignment of Assignor's Interest Jan 31, 2018
From: ZHOU, CHANGYOU; ZHANG, GUOLIANG
To: BEIGENE, LTD.
Reel/Frame 044781/0683 →
Assignment of Assignor's Interest Mar 13, 2019
From: ZHOU, CHANGYOU; ZHANG, GUOLIANG
To: BEIGENE, LTD.
Reel/Frame 048580/0706 →
Assignment of Assignor's Interest Mar 28, 2019
From: WANG, HEXIANG; ZHANG, GUOLIANG; GUO, YUNHANG; REN, BO
To: BEIGENE, LTD.
Reel/Frame 048724/0399 →
Assignment of Assignor's Interest Jul 23, 2019
From: GUO, YUNHANG; YU, DESHENG; WANG, ZHIWEI
To: BEIGENE, LTD.
Reel/Frame 049830/0832 →
Assignment of Assignor's Interest Jul 25, 2019
From: WANG, HEXIANG; ZHANG, GUOLIANG; GUO, YUNHANG; REN, BO
To: BEIGENE, LTD.
Reel/Frame 049861/0939 →
Assignment of Assignor's Interest Oct 21, 2019
From: LI, JING; ZHAO, HAIBO; WANG, ZHIWEI
To: BEIGENE, LTD.
Reel/Frame 050776/0035 →
Assignment of Assignor's Interest Sep 21, 2020
From: ZHANG, GUOLIANG; ZHOU, CHANGYOU
To: BEIGENE, LTD.
Reel/Frame 053829/0622 →
Assignment of Assignor's Interest Nov 19, 2020
From: REN, BO; ZHOU, CHANGYOU; WANG, HEXIANG
To: BEIGENE, LTD.
Reel/Frame 054421/0079 →